← All organizations
Highest phase reached
Phase 3
First clinical trial
Sep 1, 1997Last known activity
Dec 31, 2025
Timeline
1980s
- Jun 1, 1982
Theradex— Founded
Drugs by trial phase (46 distinct, 40 trials)
Phase 3 (3 own, 0 via acquisition)
Phase 2 (38 own, 0 via acquisition)
Phase 1 (5 own, 0 via acquisition)
Indications
Studied for
- Breast Neoplasms
- Carcinoma in Situ
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Cervical Intraepithelial Neoplasia
- Colorectal Neoplasms
- Esophageal Neoplasms
- Fallopian Tube Neoplasms
- Head and Neck Neoplasms
- Kidney Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Lymphoma
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Melanoma
- Mesothelioma
- Multiple Myeloma
- Myelodysplastic-Myeloproliferative Diseases
- Neoplasms
- Neoplasms, Plasma Cell
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
- Recurrence
- Small Cell Lung Carcinoma
- Triple Negative Breast Neoplasms
- Undifferentiated Connective Tissue Diseases
Recent trials (40)
- NCT07033598Lead sponsorPhase 2Dec 31, 2025
- NCT05732103CollaboratorPhase 1/Phase 2Apr 25, 2023
- NCT05077709CollaboratorPhase 2Oct 31, 2021
- NCT04638309Study directorPhase 1Sep 20, 2021
- NCT04888312CollaboratorPhase 1/Phase 2Sep 17, 2021
- NCT04419389Study directorPhase 1/Phase 2Sep 30, 2020
- NCT04383938Study directorPhase 1/Phase 2Jul 31, 2020
- NCT04203641CollaboratorPhase 1/Phase 2Dec 11, 2019
- NCT04061421CollaboratorPhase 1/Phase 2Oct 31, 2019
- NCT03617588CollaboratorPhase 2Jun 18, 2018
- NCT03402841CollaboratorPhase 3Jan 30, 2018
- NCT03008187CollaboratorPhase 1/Phase 2Jan 1, 2017
- NCT02879669CollaboratorPhase 1/Phase 2Jun 1, 2016
- NCT02529930CollaboratorPhase 1/Phase 2Aug 1, 2015
- NCT02372240CollaboratorPhase 1/Phase 2Apr 8, 2015
Details
- Founded
- Princeton, NJ, US Jun 1, 1982
- Last known activity
- Dec 31, 2025
Notes
CRO